Skip to content
Culturally and linguistically diverse, Medical Health Aged Care

MINDSET team named finalists in 2025 Eureka Prize

La Trobe University 2 mins read

A team of La Trobe University academics has been announced as a finalist in the 2025 Eureka Prize for a project that aims to improve dementia assessments for non-English speakers. 

The team, known as MINDSET, is led by Professor Bianca Brijnath. 

The project is a finalist in the Societal Impact in Science category of the prize, which is awarded to individuals or teams who, through partnership with industry, government or not-for-profit groups, have transformed research into practical solutions to address pressing global challenges.  

Professor Brijnath said the team worked with interpreters, clinicians and culturally and linguistically diverse (CALD) carers of people with dementia to co-design, trial and implement online training for interpreters. 

“Training included modules on all aspects of dementia and its impact on cognitive and linguistic ability; explaining the tools used to assess and diagnose dementia and engaging interpreters with effective interpreting strategies for cognitive assessments,” Professor Brijnath said.  

“To date, around 14 per cent of Australia’s active interpreter workforce has completed the MINDSET training and it has been rolled out to seven countries in Europe.” 

La Trobe’s Deputy Vice-Chancellor Research and Innovation Professor Chris Pakes said the work of the MINDSET team was supporting multicultural communities across the globe. 

“This important project is making a difference not only to our local CALD communities, but also internationally, demonstrating the impact of our research,” Professor Pakes said. 

Considered the ‘Oscars’ of Australian Science, the Australian Museum Eureka Prizes reward excellence in science.  

The 2025 Australian Museum Eureka Prizes will be announced at a gala award dinner at Sydney Town Hall on Wednesday, 3 September. 

The MINDSET team worked with the National Accreditation Authority for Translators and Interpreters, Dementia Australia, The Australian Institute of Interpreters & Translators, the Migrant Refugee Health Partnership, All Graduates Interpreting, NSW Health Interpreting Service, Televic, TIS National, and the Department of Health and Aged Care, as well as researchers from the National Ageing Research Institute, Monash University, University of Sydney, University of Melbourne and RMIT. 


Contact details:

Robyn Grace, [email protected] or (0420) 826 595

More from this category

  • Medical Health Aged Care, Women
  • 12/12/2025
  • 01:00
Breast Cancer Trials

Simple blood tests could help tailor treatment for aggressive breast cancer

Key Facts: Blood tests detecting circulating tumour DNA could help guide treatment for triple negative breast cancer patients Absence of tumour DNA in blood…

  • Contains:
  • Medical Health Aged Care
  • 12/12/2025
  • 00:41
Mainstay Medical Holdings plc

Mainstay Medical Announces Coverage Recommendation from the International Society for the Advancement of Spine Surgery (ISASS) for ReActiv8

DUBLIN--BUSINESS WIRE-- Mainstay Medical Holdings plc today announced that the International Society for the Advancement of Spine Surgery (ISASS) has issued recommendations and coverage criteria for the use of restorative neurostimulation for the treatment of chronic mechanical low back pain associated with multifidus muscle dysfunction. ReActiv8® restorative neurostimulation is the only therapy approved in the United States, Europe and Australia for this indication. The Statement, which affirms ISASS’ support for coverage by payers of implantable restorative neurostimulation in appropriately selected patients, was published in the December issue of the International Journal of Spine Surgery and can be accessed here: https://www.ijssurgery.com/content/early/2025/12/10/8833.…

  • Government Federal, Medical Health Aged Care
  • 11/12/2025
  • 14:21
Hepatitis Australia and ASHM

Australia’s leading hepatitis experts reaffirm support for birth-dose hepatitis B vaccination

Australia’s foremost hepatitis researchers and clinicians have released a joint expert statement confirming that Australia’s recommendation remains unchanged: all medically stable newborns who meet the weight threshold should receive their first dose of the hepatitis B vaccine within 24 hours of birth. The statement follows international attention after a U.S. advisory panel recommended reversing its long-standing advice that infants receive the hepatitis B vaccine at birth. Hepatitis Australia CEO Lucy Clynes said parents and healthcare professionals should remain confident in Australia’s long-standing, evidence-based approach. “Australia’s advice has not changed. The hepatitis B birth-dose vaccination is safe, effective and one of…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.